Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.

Trial Profile

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Sunitinib
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms OCLURANDOM
  • Most Recent Events

    • 11 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTriasl.gov record.
    • 05 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top